These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33301829)

  • 21. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
    Liu RC
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sacubitril/Valsartan in Clinical Practice: A Report of 2 Cases.
    Cosentino E
    Cardiology; 2017; 138 Suppl 1():7-10. PubMed ID: 29262399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
    King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
    JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
    Kario K
    Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction.
    Xi Q; Chen Z; Li T; Wang L
    J Int Med Res; 2022 Jan; 50(1):3000605211067909. PubMed ID: 34986674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
    Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA
    Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.
    Pogge EK; Davis LE
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):143-151. PubMed ID: 29455335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience.
    Farmakis D; Bistola V; Karavidas A; Parissis J
    Int J Cardiol; 2016 Nov; 223():781-784. PubMed ID: 27573608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
    Nguyen E; Weeda ER; White CM
    J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
    Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials.
    Abdin A; Schulz M; Riemer U; Hadëri B; Wachter R; Laufs U; Bauersachs J; Kindermann I; Vukadinović D; Böhm M
    ESC Heart Fail; 2022 Dec; 9(6):3737-3750. PubMed ID: 35921043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
    Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
    JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
    Vardeny O; Claggett B; Kachadourian J; Pearson SM; Desai AS; Packer M; Rouleau J; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    Circ Heart Fail; 2018 Apr; 11(4):e004745. PubMed ID: 29643067
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.